頭孢洛扎/塔唑巴坦
參考文獻

↑  . Drugs.com. 2019-06-14  [2020-05-14]. （原始内容存档于2020-11-25）.
↑  . Therapeutic Goods Administration (TGA). 2022-06-21  [2023-04-10]. （原始内容存档于2023-04-10）.
↑  . Health Canada. 2016-05-04  [2024-04-07]. （原始内容存档于2020-02-20）.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  . European Medicines Agency (EMA). 2018-09-17  [2020-05-14]. （原始内容存档于2020-05-06）.  Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1 2 3 4  . DailyMed. 2019-06-03  [2020-05-14]. （原始内容存档于2020-05-10）.
1 2 3 4 5 6 7 8  . U.S. Food and Drug Administration (FDA) (新闻稿).   [2015-06-02]. （原始内容存档于2015-05-09）.   本文含有此來源中屬於公有领域的内容。
↑  Long TE, Williams JT. . Expert Opinion on Investigational Drugs. October 2014, 23 (10): 1375–87. PMID 24956017. S2CID 5234167. doi:10.1517/13543784.2014.930127.
↑  Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F,  et al. . Drugs. January 2014, 74 (1): 31–51. PMID 24352909. S2CID 44694926. doi:10.1007/s40265-013-0168-2 .
↑  Cada, Dennis J.; Wageman, Jesse. . Hospital Pharmacy. 2015-06-18, 50 (6): 526–533  [2024-07-30]. doi:10.1310/hpj5006-526. （原始内容存档于2024-07-15）.
↑  . U.S. Food and Drug Administration (FDA). 1999-12-24  [2020-05-14]. （原始内容存档于2020-10-27）.
↑  World Health Organization. . Geneva: World Health Organization. 2023. hdl:10665/371090 . WHO/MHP/HPS/EML/2023.02.
↑  Murano K, Yamanaka T, Toda A, Ohki H, Okuda S, Kawabata K,  et al. . Bioorganic & Medicinal Chemistry. March 2008, 16 (5): 2261–75. PMID 18082409. doi:10.1016/j.bmc.2007.11.074.
1 2  Shortridge D, Pfaller MA, Castanheira M, Flamm RK. . Microbial Drug Resistance. June 2018, 24 (5): 563–577. PMID 29039729. S2CID 4873637. doi:10.1089/mdr.2017.0266 .
↑  Snydman DR, McDermott LA, Jacobus NV. . Antimicrobial Agents and Chemotherapy. February 2014, 58 (2): 1218–23. PMC 3910869 . PMID 24277025. doi:10.1128/AAC.02253-13.
1 2  Hong MC, Hsu DI, Bounthavong M. . Infection and Drug Resistance. November 2013, 6: 215–23. PMC 3848746 . PMID 24348053. doi:10.2147/idr.s36140  （英语）.
↑  Cluck D, Lewis P, Stayer B, Spivey J, Moorman J. . American Journal of Health-System Pharmacy. December 2015, 72 (24): 2135–46. PMID 26637512. doi:10.2146/ajhp150049.
↑  Chandorkar G, Xiao A, Mouksassi MS, Hershberger E, Krishna G. . Journal of Clinical Pharmacology. February 2015, 55 (2): 230–9. PMC 4303958 . PMID 25196976. doi:10.1002/jcph.395.
↑  Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. . Antimicrobial Agents and Chemotherapy. 2014-04-01, 58 (4): 2249–55. PMC 4023800 . PMID 24492369. doi:10.1128/AAC.02151-13 .
1 2  Goodlet KJ, Nicolau DP, Nailor MD. . Therapeutics and Clinical Risk Management. 2016-12-01, 12: 1811–1826. PMC 5140030 . PMID 27942218. doi:10.2147/tcrm.s120811  （英语）.
↑  Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. . Antimicrobial Agents and Chemotherapy. June 2012, 56 (6): 3086–91. PMC 3370713 . PMID 22450972. doi:10.1128/AAC.06349-11 .
↑   (PDF). fda.gov.   [2024-07-30]. （原始内容存档 (PDF)于2021-05-17）.
↑  Karlowsky, James A; Lob, Sibylle H. . International Journal of Antimicrobial Agents. May 2023, 61 (5): 106772  [2024-0715]. doi:10.1016/j.ijantimicag.2023.106772. （原始内容存档于2024-12-25）.  请检查|access-date=中的日期值 (帮助)
1 2  Sorbera, Maria; Chung, Elizabeth. Pharmacy and Therapeutics https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264669/. December 2014  [2024-07-15]. （原始内容存档于2024-07-15）.  缺少或|title=为空 (帮助)
↑  Cada, Dennis J.; Wageman, Jesse. . Hospital Pharmacy. June2015, 50 (6): 5006–526  [2024-07-15]. （原始内容存档于2024-07-15）.  请检查|date=中的日期值 (帮助)
↑  Sorbera M, Chung E, Ho CW, Marzella N. . Pharmacy & Therapeutics. December 2014, 39 (12): 825–32. PMC 4264669 . PMID 25516692.
↑  U. S. Patent Application No. WO2016025839 (A1) 2016